What's with the Imugene share price today?

Investors appear to be pleased with the immuno‐oncology biotech's progress.

| More on:
Medical technicians wearing white medical coats conduct a test in a laboratory.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Imugene share price is up 4% today after the company released its March quarter cash flow and activities report
  • Imugene is currently conducting several clinical trials of immunotherapies that seek to activate the immune system of cancer patients to treat and kill off cancerous tumours
  • The biotech company commenced the Australian arm of its VAXINIA trial during the quarter, with Tasman Oncology Research in South Australia being the first cancer hospital to sign up 

The Imugene Limited (ASX: IMU) share price lifted 4% today after the company released its March quarter report.

Imugene shares gained half a cent and were swapping hands at 13 cents in earlier trade but have since returned to their closing price yesterday of 12.5 cents.

The S&P/ASX All Ordinaries Index (ASX: XAO) has also lost a little ground in the late afternoon and is currently trading just 0.13% higher.

Let's take a look at today's report from the ASX biotech share.

Imugene share price goes green

Imugene is a clinical-stage immuno‐oncology company developing virotherapies that seek to activate the immune system of cancer patients to treat and kill off cancerous tumours.

There was nothing new in today's report other than a few financial metrics. However, investors appear pleased with the company's financial position and the progress it has made in its trials over the period.

Cancer trials

Key developments during the quarter include the first patients being dosed in the VAXINIA and Pembrolizumab combination study. VAXINIA is a cancer-killing virus.

Patients in the intravenous (IV) and intratumoral (IT) cohorts received their first dose of the immunotherapy.

Imugene aims to recruit up to 100 patients across several trial sites in the United States and Australia for this trial. It got approval to start trials in Australia during the quarter. The first hospital involved is Tasman Oncology Research in South Australia. Imugene is opening other sites now.

Imugene also began its multicenter Phase 1 MAST trial. The trial involves patients with metastatic or advanced solid tumours who have had at least two prior lines of existing standard cancer treatment.

Imugene's preclinical laboratory and animal studies showed VAXINIA reduces the size of colon, lung, breast, ovarian and pancreatic cancer tumours.

New patent

Imugene also received a US patent until 2038 for its B-cell activating immunotherapy PD1-Vaxx.

PD1-Vaxx is in clinical development for non-small cell lung cancer (NSCLC). Imugene intends to run a clinical trial that combines PD1-Vaxx with the immune checkpoint inhibitor drug, atezolizumab.

Financials

In terms of the company's financial position, Imugene had $151.5 million in cash or equivalents at the end of the quarter.

The company spent $10.6 million net cash on operating activities. Direct research and development and staff costs accounted for 83% of the expenditure.

Spreading the word on progress

Imugene presented at several conferences during the quarter, including the prestigious J.P. Morgan Healthcare Conference, which attracts thousands of global investors every year.

The company also presented its HER-Vaxx & CF33 platforms at the ASCO Gastrointestinal Cancers Symposium, which attracts thousands of oncologists, clinical researchers, and academics.

Imugene also gave a presentation at the NWR Healthcare Conference.

In addition, the biotech company announced positive imaging data for its oncolytic virotherapy candidate, CHECKvacc, last week.

Imugene share price snapshot

The Imugene share price is down 9.3% in 2023 so far.

Its peers in the S&P/ASX 200 Health Care Index (ASX: XHJ) have gone up 8.9%.

Created with Highcharts 11.4.3Imugene PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »